About Us


Our inventions and discoveries over 30+ years of academic research have brought the science of Catalytic Immunotherapy and E-vaccines to the brink of medical intervention.

We are now focused on raising capital to develop marketable products and services:

  • Two catabodies to treating amyloid diseases of the heart, musculoskeletal system and brain (catabodies to transthyretin, amyloid β and tau) and a lead E-vaccine for prophylaxis and therapy of HIV infection.
  • Expanding the medical reach of the technology platform by on-demand production of catabodies and E-vaccines to any pre-specified target protein.


Business Development Consultant

Scientific Advisors:

Robert P. Friedland, M.D. Professor,
University of Louisville, Louisville, KY
Joel Buxbaum, M.D. Professor,
Scripps Research Institute, La Jolla, CA
Miguel A. Escobar, M.D. Professor,
University of Texas Health Science Center, Houston, TX
Carl Hanson, Ph.D. CLIA Lab Director
California Department of Public Health, Richmond, CA
Seth Pincus, Ph.D. Professor,
Montana State University, Bozeman, MT